Self-adjuvanting therapeutic peptide-based vaccine induce CD8+ cytotoxic T lymphocyte responses in a murine human papillomavirus tumor model

Tzu Yu Liu, Ashwini Kumar Giddam, Waleed M. Hussein, Zhongfan Jia, Nigel A.J. McMillan, Michael J. Monteiro, Istvan Toth, Mariusz Skwarczynski

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)


Vaccine candidates for the treatment of human papillomavirus (HPV)-associated cancers are aimed to activate T-cells and induce development of cytotoxic anti-tumor specific responses. Peptide epitopes derived from HPV-16 E7 oncogenic protein have been identified as promising antigens for vaccine development. However, peptide-based antigens alone elicit poor cytotoxic T lymphocyte (CTL) responses and need to be formulated with an adjuvant (immunostimulant) to achieve the desired immune responses. We have reported the ability of polyacrylate 4-arm star-polymer (S4) conjugated with HPV-16 E744-57 (8Qmin) epitope to reduce and eradicate TC-1 tumor in the mouse model. Herein, we have studied the mechanism of induction of immune responses by this polymer-peptide conjugate and found prompt uptake of conjugate by antigen presenting cells, stimulating stronger CD8+ rather than CD4+ or NK cell responses.

Original languageEnglish
Pages (from-to)3-8
Number of pages6
JournalCurrent Drug Delivery
Issue number1
Publication statusPublished - Oct 2014
Externally publishedYes


  • Cytotoxic T lymphocyte (CTL) responses
  • Human papillomavirus
  • Peptide subunit vaccine
  • polyacrylate
  • Selfadjuvanting
  • Star-polymer
  • Therapeutic anticancer vaccine


Dive into the research topics of 'Self-adjuvanting therapeutic peptide-based vaccine induce CD8<sup>+</sup> cytotoxic T lymphocyte responses in a murine human papillomavirus tumor model'. Together they form a unique fingerprint.

Cite this